Lipid Nano-particles

Binding analytics - affinity measurements
I'm Interested

How does FIDA accelerate LNP development?

01

Efficiency thanks to simultaneous measurements

  • Absolute size (Rh) of your lipid nanoparticle
  • PDI - Polydispersity index – transparency on sample homogeneity
  • Quantification of aggregates
  • Simultaneous measurement of PDI, aggregation and size allows to check sample quality in every run
02

Affinity measurements

  • Affinity assessment (Kd) of binding to lipid nanoparticle
  • Quantification of binding sites
03

Small sample size

  • Down to 40 nL of LNP solution for sizing and sample quality measurement
  • Down to 4 ul for affinity measurement
04

Perfect for stability testing

  • Temperature control (5-55 degrees C) - you can detect LNP stability over time
  • Triple temperature control sensors
05

Flexible buffer conditions

  • Serum, plasma or cell lysate
  • Any pH or ionic strength
  • Screening of formulation buffers: aggregation quantification, size, and polydispersity all measured in one assay
06

Makes researchers more efficient

  • Increases your efficiency - thanks to simultaneous size characterisation and stability testing
  • Saves sample material, which lowers the cost of research
  • Walk-away automation frees up time
07

Technically optimised for work with lipid nanoparticles

  • In solution technology - enables the users to work in any solution and avoid surface immobilisation
  • In solution technology - enables the users to work in any solution and avoid surface immobilisation

Benefits

Absolute size measurement
Assessment of number of binding sites
Single technology for development, optimisation and scaling
Flexible conditions optimization
Informed stability testing
Time-saving automation

Features

Built-in Quality Control
Aggregation quantification, size,  polydispersity - all in one assay
No buffer constraints
Direct measurement of Rh
Affinity measurements
Triple temperature control

Measures

Accurate determination of dilute phase concentration
Relative droplet size distributions
Kinetics of droplet formation and maturation into amyloid fibrils
Determination of binding affinity between the polypeptide undergoing LLPS and LLPS-modulating compounds

One technology throughout the workflow:

01
Development:
- Sizing
- Polydispersity
- Binding characteristics
02
Optimization
- Buffer screening for stability
- Stability testing overtime and at different temperature
03
Scaling for production
- Stability testing
- Binding assessment

Targeting common challenges in research on lipid nanoparticles

Challenge
Size and Stability Control
FlDA allows its users to determine the absolute size (Rh) of lipid nanoparticles under dynamic flow conditions. It also allows to quantify aggregates, that may affect the overall quality and performance of the LNPs under development.
Biocompatibility and Toxicity
FIDA users work in flexible buffer conditions (serum, plasma or cell lysate), simulating different physiological environments.
Scalability and Manufacturing
FIDA is employed as a quality control tool during the manufacturing process to ensure consistency and stability of the product.
“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna, sid aliqua. Ut enim ad minim veniam.”
lorem ipsum dolor
ceo, company name
“Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo”
lorem ipsum dolor
ceo, company name
“At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias.”
lorem ipsum dolor
ceo, company name

Become a user

Your laboratory instruments should serve you, not the other way around. We’re happy to help you.